Claims for Patent: 9,539,302

Summary for Patent: 9,539,302

Title:	Safe desmopressin administration
Abstract:	Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Inventor(s):	Fein; Seymour (New Canaan, CT)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/378,778
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,539,302
Patent Claims:	1. An intranasal spray device for consistently achieving a low desmopressin blood concentration thereby to produce safe antidiuresis in human patients and to minimize the likelihood that a patient will suffer from hyponatremia, the device comprising a reservoir having disposed therein a composition comprising desmopressin; an outlet in communication with the reservoir comprising a nozzle which dispenses a desmopressin dose in the form of a plume ejected over a time interval, the plume comprising a volume of moving droplets together defining a conical volume having a central axis and an apex at the nozzle of the spray device, wherein the droplet density (number of droplets per unit volume) within the conical volume increases in a direction normal to the axis, the droplets together comprising between about 0.05 .mu.g and 5.0 .mu.g desmopressin, the plume serving to increase contact of the droplets with intranasal luminal mucosal surfaces, wherein said droplets further comprise: (a) an oil-in-water emulsion; and (b) a permeation enhancer. 2. The device of claim 1 wherein an axial cross section of the conical volume at a surface about 3 cm or less from its apex describes an annular disk of droplets. 3. The device of claim 1 wherein the plume is effective to deliver transmucosally sufficient desmopressin to the bloodstream of a patient weighing 70 kg or 35 kg to produce a desmopressin blood concentration less than 18 pg/ml. 4. The device of claim 3 wherein the plume is effective to produce a desmopressin blood concentration less than 15 pg/ml. 5. The device of claim 3 wherein the plume is effective to produce a desmopressin blood concentration less than 10 pg/ml. 6. The device of claim 1 wherein the droplets together comprise between about 0.2 .mu.g and 5.0 .mu.g desmopressin. 7. The device of claim 1 wherein said permeation enhancer comprises a cyclopentadecanolide. 8. The device of claim 1 wherein the droplets together comprise about 1.5 .mu.g desmopressin. 9. The device of claim 1 wherein the droplets together comprise about 0.75 .mu.g desmopressin.